Monday, Jul 23, 2001

Genentech Invites Public to Listen to Webcast of July 31 Discussion of Xanelim Phase III Results

South San Francisco, Calif. -- July 23, 2001 --

Genentech, Inc. (NYSE: DNA) invites investors and the general public to listen to a webcast of a discussion of Xanelim™ Phase III results for patients with moderate-to-severe plaque psoriasis. The results will be presented at an evening symposium at the Summer American Academy of Dermatology (AAD) meeting in Anaheim, California on July 30, 2001. The webcast will begin at 7:00a.m. PDT on July 31, 2001. The webcast can be accessed by going to Genentech's website at and will be archived and available for replay until 9:00a.m. PDT on August 7, 2001.

A telephone replay of the webcast will be available beginning at 9:00 a.m. PDT on July 31, 2001 until 9:00 a.m. PDT on August 7, 2001. Access numbers for this replay are: 1-800-633-8284 (domestic) and 1-858-812-6440 (international); passcode number is 19401122.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fourteen of the currently approved biotechnology products stem from or are based on Genentech science. Genentech markets nine biotechnology products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.

# # #